Study of guselkumab for psoriatic arthritis in real-world care
Part of Bones, joints & muscles, Skin clinical trials.
This study is testing how well guselkumab works for people with psoriatic arthritis who are starting it in everyday medical practice. Researchers want to see if the drug helps reduce joint swelling and tenderness, and if it can improve enthesitis (pain where tendons attach to bone).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriatic arthritis for at least 6 months with active symptoms (like tender/swollen joints or high inflammation).
- You'll be starting guselkumab as part of your regular care, not in a research setting.
- You have not taken guselkumab before, and have taken at most one other biologic drug or apremilast/deucravacitinib.
- You haven't used JAK inhibitors (like tofacitinib, baricitinib, etc.).
- You have at least one tender spot where tendons attach to bone (enthesitis) and an ultrasound confirms inflammation there.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Hear when a new Arthritis, Psoriatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.